List of Excipients in Branded Drug TOSYMRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Upsher-Smith Laboratories LLC	TOSYMRA	sumatriptan	0245-0812	CITRIC ACID MONOHYDRATE
Upsher-Smith Laboratories LLC	TOSYMRA	sumatriptan	0245-0812	MONOBASIC POTASSIUM PHOSPHATE
Upsher-Smith Laboratories LLC	TOSYMRA	sumatriptan	0245-0812	N-DODECYL .BETA.-D-MALTOSIDE
Upsher-Smith Laboratories LLC	TOSYMRA	sumatriptan	0245-0812	SODIUM CHLORIDE
Upsher-Smith Laboratories LLC	TOSYMRA	sumatriptan	0245-0812	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
Upsher-Smith Laboratories LLC	TOSYMRA	sumatriptan	0245-0812	WATER

TOSYMRA Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

TOSYMRA is a prescription sumatriptan nasal spray that uses an absorption-enhancing excipient system to deliver 10 mg of sumatriptan through the nasal mucosa. Its commercial value is tied less to the active ingredient, which is generic, than to the formulation, intranasal delivery performance, device configuration, and patient convenience. The strongest lifecycle opportunities are preservative-free delivery, improved tolerability, pediatric and adolescent use, combination therapy, and differentiated devices.

What is TOSYMRA and how does its formulation work?

TOSYMRA is a 10 mg sumatriptan nasal spray for the acute treatment of migraine with or without aura in adults. The labeled dose is one spray into one nostril. A second dose may be administered after at least two hours, with a maximum of 30 mg in 24 hours.[1]

The formulation is an aqueous nasal solution containing sumatriptan succinate and excipients designed to support drug solubilization, chemical stability, pH control, preservation, and nasal absorption.

Product attribute	TOSYMRA profile
Active ingredient	Sumatriptan succinate
Delivered dose	10 mg sumatriptan per actuation
Dosage form	Intranasal solution
Administration	One spray into one nostril
Repeat dosing	May repeat after at least two hours
Maximum daily dose	30 mg
Therapeutic category	Acute migraine treatment
FDA pathway	505(b)(2) new drug application
Key formulation concept	Nasal absorption enhancement
Primary commercial market	U.S. prescription migraine market

The use of an absorption-enhancing excipient is central to TOSYMRA’s differentiation. Intranasal sumatriptan products must overcome mucociliary clearance, limited residence time, variable nasal absorption, and the barrier properties of the nasal epithelium. A formulation that increases epithelial permeability can improve systemic exposure without requiring a larger spray volume.

What excipients are used in TOSYMRA?

The FDA prescribing information identifies the principal inactive ingredients as benzalkonium chloride, citric acid monohydrate, dodecyl maltoside, edetate disodium, sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate, sulfuric acid, sodium hydroxide, and water for injection.[1]

Excipient	Primary formulation function	Commercial or technical relevance
Dodecyl maltoside	Nasal absorption enhancer and surfactant	Core differentiation element; potential IP and regulatory scrutiny
Benzalkonium chloride	Antimicrobial preservative	Supports multidose-container microbiological control; may raise chronic nasal tolerability concerns
Citric acid monohydrate	Buffer component and pH adjustment	Supports pH control and product stability
Sodium phosphate dibasic	Buffer component	Controls formulation pH and ionic environment
Sodium phosphate monobasic	Buffer component	Works with dibasic phosphate to maintain pH
Edetate disodium	Chelating agent	May improve stability by binding trace metals
Sulfuric acid	pH adjustment	Used for final pH control
Sodium hydroxide	pH adjustment	Used for final pH control
Water for injection	Vehicle	Aqueous carrier for the nasal solution

The most strategically important excipient is dodecyl maltoside. It is a nonionic surfactant used in some intranasal delivery systems to increase membrane permeability and improve absorption. Its role creates a potential formulation barrier for generic manufacturers because a product with the same active ingredient but a different enhancer may require comparative pharmacokinetic, safety, and local-tolerability evidence.

How important is dodecyl maltoside to TOSYMRA’s commercial position?

Dodecyl maltoside supports TOSYMRA’s product differentiation in four ways.

First, it may increase the fraction of sumatriptan absorbed across the nasal epithelium. Second, it can help reduce reliance on high drug loading or large spray volumes. Third, its use can support a 505(b)(2) development strategy by linking the new product to an established sumatriptan reference while relying on formulation-specific clinical and pharmacokinetic data. Fourth, the enhancer may create a higher technical hurdle for an ANDA applicant that seeks to demonstrate pharmaceutical equivalence and bioequivalence.

The excipient also creates constraints. Surfactants can affect epithelial integrity, local irritation, taste, burning sensation, and tolerability. The commercial advantage therefore depends on maintaining adequate permeability enhancement without producing a noticeable tolerability penalty.

What formulation parameters are most important?

The critical quality attributes include:

• Dodecyl maltoside concentration and grade
• Sumatriptan concentration and salt form
• Formulation pH
• Osmolality
• Spray volume
• Droplet-size distribution
• Pump delivery reproducibility
• Preservative concentration
• Microbiological quality
• Impurity profile
• Container-closure compatibility
• Nasal deposition pattern

A change in surfactant concentration can affect both exposure and local tolerability. A change in pump geometry can alter delivered dose, plume characteristics, and deposition site even when the bulk formulation remains unchanged.

What excipient opportunities exist for next-generation TOSYMRA products?

The clearest opportunity is a preservative-free, unit-dose product. TOSYMRA uses benzalkonium chloride, which is commercially useful in a multidose system but can create concerns regarding repeated nasal exposure. A preservative-free presentation could improve positioning for patients with frequent migraine attacks, nasal sensitivity, allergic rhinitis, or concern about chronic preservative exposure.

Preservative-free formulation

A unit-dose ampoule, blister, or single-use nasal device could eliminate the need for benzalkonium chloride. The tradeoff is higher packaging cost, more complex supply-chain handling, and potentially lower convenience for patients who need repeat doses.

A preservative-free product could support:

• Premium pricing
• Pharmacy benefit differentiation
• Improved use in high-frequency migraine
• Reduced local-irritation concerns
• Hospital and specialty-pharmacy positioning
• Potential pediatric development

Alternative absorption enhancers

Potential replacement excipients include other nonionic surfactants, cyclodextrins, bile-salt derivatives, fatty-acid systems, and mucoadhesive polymers. Each alternative would require evaluation for nasal toxicity, systemic exposure, extractables and leachables, and compatibility with the pump.

The commercial objective would not be to substitute excipients solely for cost reduction. A successful replacement should provide a measurable benefit, such as lower irritation, longer residence time, improved absorption consistency, reduced variability in congested nasal passages, or improved shelf stability.

Mucoadhesive systems

Mucoadhesive excipients could extend nasal residence time and reduce post-dose drainage. Candidates may include selected cellulose derivatives, polyvinyl alcohol, carbomers, or other pharmaceutically acceptable polymers. The main risk is that excessive viscosity can impair spray performance and create inconsistent dose delivery.

Lower-volume and high-concentration systems

A higher-concentration formulation could reduce spray volume and improve patient acceptance. It would require control of solubility, osmolality, viscosity, crystallization risk, and pump metering. High-concentration systems may be particularly valuable for patients who dislike nasal products or experience throat runoff.

What commercial opportunities exist for TOSYMRA?

TOSYMRA competes in a broad acute migraine market that includes oral triptans, orally disintegrating tablets, injectable sumatriptan, other nasal triptans, gepants, and dihydroergotamine products. Its strongest positioning is for patients who need nonoral delivery because of nausea, vomiting, gastroparesis, rapid symptom escalation, or a preference for nasal administration.

Opportunity	Product concept	Commercial rationale
Preservative-free	Single-use nasal spray	Improves tolerability positioning and supports premium pricing
Pediatric extension	Lower-dose or weight-adjusted product	Expands addressable population, subject to FDA development
High-frequency migraine	Lower-irritation nasal formulation	Targets repeat users and specialty-care patients
Device redesign	Ergonomic, dose-confirming pump	Improves adherence and reduces administration errors
Combination therapy	Sumatriptan plus antiemetic or adjunct	Addresses migraine symptoms beyond vasoconstriction
International licensing	Regional rights for nasal triptan platform	Monetizes formulation and device know-how
Contract development	Nasal delivery platform services	Creates non-product revenue from excipient and device expertise
Private-label supply	Branded or authorized-generic arrangements	Increases manufacturing utilization and market reach

How does TOSYMRA compare with other sumatriptan products?

TOSYMRA’s principal advantage is rapid nonoral administration without the needle burden of subcutaneous injection. Its principal limitations are nasal tolerability, variable deposition, device dependence, and competition from low-cost generic tablets and nasal products.

Product type	Main advantage	Main limitation	TOSYMRA positioning
Generic oral sumatriptan	Low cost and broad availability	Poor suitability during nausea or vomiting	Premium nonoral alternative
Sumatriptan injection	Rapid and predictable exposure	Needle use and injection burden	Needle-free rapid-delivery alternative
Sumatriptan nasal spray	Nonoral administration	Nasal irritation and device variability	Differentiation through enhancer and device
Oral gepants	No vasoconstrictive triptan mechanism	Higher price; onset and access vary	Alternative mechanism competitor
Dihydroergotamine nasal spray	Nonoral migraine treatment	More complex tolerability and use profile	Competing specialty nasal therapy

TOSYMRA cannot compete effectively on active-ingredient cost. Its economic case depends on adherence, speed of use, convenience, formulary placement, and clinical value in patients who do not obtain adequate benefit from oral therapy.

What patent and regulatory issues affect TOSYMRA?

TOSYMRA is a small-molecule product, so biosimilar risk does not apply. Competitive entry would come through an ANDA, a 505(b)(2) application, an authorized generic, or a competing branded product.

Orange Book and patent strategy

The relevant intellectual-property categories are:

1. Formulation patents covering the absorption-enhancer system.
2. Device patents covering the nasal pump, actuator, container, or dose-metering system.
3. Method-of-use patents covering specific migraine populations or dosing regimens.
4. Manufacturing patents covering formulation preparation, filling, or device assembly.
5. Trade secrets covering excipient grades, concentration ranges, process controls, and spray-performance specifications.

Formulation claims are potentially stronger than broad claims to sumatriptan because the active ingredient is long established and widely available. Claims that require a specific enhancer concentration, pH range, spray volume, pharmacokinetic profile, or local-tolerability parameter may create more meaningful differentiation than claims directed only to the presence of sumatriptan.

The FDA Orange Book is the source of record for listed patents and regulatory exclusivity. Any Paragraph IV challenge would likely focus on noninfringement, invalidity, or the applicant’s ability to design around the enhancer or device claims. The commercial effect depends on the listed patent’s expiration date, pediatric extension, regulatory exclusivity, and the scope of any settlement agreement.

Generic launch scenarios

Scenario	Likely effect
ANDA using the same active ingredient but different enhancer	May face formulation equivalence and bioequivalence complexity
505(b)(2) product using a different nasal enhancer	Could obtain differentiated labeling but may require clinical studies
Authorized generic	Rapid price compression with lower regulatory risk
Device-focused competitor	May preserve formulation differentiation but compete on convenience
Preservative-free entrant	Could take share among frequent users and sensitive patients
Settlement with first ANDA filer	Entry timing may be delayed or controlled by licensing terms

A generic manufacturer may avoid direct copying of TOSYMRA’s excipient system by using a different absorption enhancer. That approach can reduce literal infringement risk but may increase development cost and regulatory requirements.

What manufacturing and supply-chain barriers protect the product?

The manufacturing process must control surfactant dispersion, active-ingredient solubilization, pH adjustment, microbiological quality, and filling accuracy. Nasal sprays also require tight control of pump assembly and actuation performance.

Key barriers include:

• Consistent sourcing of pharmaceutical-grade dodecyl maltoside
• Control of surfactant purity and degradation products
• Compatibility between formulation and pump components
• Container-closure integrity
• Low extractables and leachables
• Dose uniformity over the product shelf life
• Microbiological control in a multidose package
• Stability under temperature excursions
• Reliable high-speed assembly and filling

These barriers may support manufacturing know-how even when formal patent protection is narrow. A competitor that copies the qualitative excipient list may still fail to reproduce nasal deposition, dose consistency, or systemic exposure.

What licensing and partnership opportunities are available?

The product creates three licensing pathways.

First, regional licensing could transfer U.S.-validated formulation and device technology to markets where nasal triptans have limited competition. Second, co-development agreements could finance preservative-free, pediatric, or combination products. Third, platform licensing could offer the absorption-enhancer technology for other intranasal drugs, including peptides, rescue medicines, and central nervous system therapies.

The most valuable deal structure would likely combine upfront payment, development milestones, commercial milestones, and royalties tied to net sales. A formulation-only license may command less value than a package containing the enhancer, device, manufacturing process, clinical data, and regulatory dossier.

How strong is the TOSYMRA patent estate?

The formulation concept has potentially meaningful technical defensibility because dodecyl maltoside, nasal delivery performance, and device specifications can be claimed in combination. The estate is weaker against competitors that use a different enhancer, different device, or different concentration range.

Patent strength should be assessed across five dimensions:

Factor	Assessment
Active-ingredient protection	Weak, because sumatriptan is established and generic
Formulation protection	Potentially meaningful if claims require defined enhancer and performance parameters
Device protection	Relevant if the pump or actuation system is proprietary
Method-of-use protection	Narrower and vulnerable to label carve-outs
Manufacturing protection	Potentially durable through trade secrets and process know-how

The most defensible commercial position is a layered estate covering formulation composition, nasal deposition, device operation, manufacturing controls, and selected patient populations.

Key Takeaways

• TOSYMRA’s differentiation depends on intranasal delivery rather than sumatriptan itself.
• Dodecyl maltoside is the key strategic excipient because it supports nasal absorption and may create formulation-development barriers.
• Benzalkonium chloride enables multidose preservation but creates a clear opportunity for a preservative-free successor.
• The strongest lifecycle opportunities are unit-dose delivery, lower-irritation formulations, pediatric development, device redesign, and combination therapy.
• Generic competition is likely to focus on formulation substitution, device design-around, and 505(b)(2) development.
• Patent value is concentrated in formulation, device, and manufacturing claims, not in the sumatriptan molecule.
• A preservative-free, lower-volume product could support premium positioning if it demonstrates improved tolerability or adherence.
• The broader excipient platform may have licensing value beyond migraine treatment.

FAQs

Can dodecyl maltoside be replaced in a TOSYMRA follow-on product?

Yes. A competitor could use another absorption enhancer, but the replacement would require evidence supporting nasal safety, exposure, dose delivery, stability, and regulatory equivalence.

Is TOSYMRA suitable for an authorized-generic strategy?

Yes. An authorized generic could use the approved formulation and device, reducing development risk. The commercial tradeoff would be lower net pricing and potential erosion of the branded product.

Could TOSYMRA be reformulated without benzalkonium chloride?

Yes. A unit-dose or other preservative-free container could remove the need for benzalkonium chloride, subject to stability, sterility or microbiological-control requirements, packaging validation, and FDA review.

What is the most valuable TOSYMRA lifecycle patent claim?

A claim combining the specific absorption enhancer, concentration range, nasal spray parameters, and measurable pharmacokinetic or deposition performance would generally provide more product-specific protection than a broad claim to intranasal sumatriptan.

Does TOSYMRA face biosimilar competition?

No. Sumatriptan is a small molecule. Competitive follow-on products would generally use the ANDA or 505(b)(2) pathways rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). Tosymra (sumatriptan) nasal spray prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (1999). Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation. FDA.

4. U.S. Food and Drug Administration. (2019). Applications covered by Section 505(b)(2). FDA.

5. U.S. Food and Drug Administration. (2022). ANDAs for certain highly purified synthetic peptides. FDA.